Loading rounds…
Loading rounds…
Explore funding rounds, the companies behind them and the investors taking part.
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| VT Develops intelligent, logic-gated therapeutics for solid tumors | $61M | Series A | Biotech | China | Investors | |
| N |
Ranked by rounds participated in · All time
AusperBio, Abcuro, Infinimmune
Epicrispr Biotechnologies, Draig Therapeutics, Triveni Bio
LifeMine Therapeutics, Ollin Biosciences, SonoThera
Leal Therapeutics, Khartis Therapeutics, Vedana Therapeutics
Leal Therapeutics, Amplifica Holdings Group, InduPro
Explore published rounds while the next edition is being prepared.
Develops implant for treating articular cartilage defects in the knee
Develops implant for treating articular cartilage defects in the knee
| $4.1M |
| Seed2Seed |
| Biotech |
| United States |
| Investors |
| V Provides intelligent software platforms for oncology care | $43M | Undisclosed | Biotech, Healthtech | United States | Investors |
| MT Mirador TherapeuticsCompany profile Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases | $250M | Series B | Biotech | United States | Investors |
| AA Uses Causal AI to reformulate complex small-molecule drugs | $5M | Seed | Biotech, AI | United States | Investors |
| TB Trailhead BiosystemsCompany profile Develops human cells with defined molecular and functional properties for drug discovery and regenerative medicine Develops human cells with defined molecular and functional properties for drug discovery and regenerative medicine | $20M | Growth | Biotech | United States | Investors |
| OT Oricell TherapeuticsCompany profile Develops next-generation cell therapies for oncology and immunology Develops next-generation cell therapies for oncology and immunology | $70M | Series C1Series C+ | Biotech | China | Investors |
| JT Develops regenerative biologics to restore tissue function | $33.5M | Series B | Biotech | United States | Investors |
| O Develops AI-based predictive genomics approach to target discovery | £2.5M | Seed | Biotech | United Kingdom | Investors |
| KT Develops inhaled therapies for severe respiratory diseases | $103M | Series B | Biotech | United States | Investors |